Psychedelic Front Runners MindMed , BioXcel Patent System To Identify Agitation

This article by Gaurav Dubey was originally published on Microdose Psychedelic Insights and appears here with permission.

The psychedelic front-runners at MindMed (NASDAQ: MNMD) have announced their partnership with BioXcel Therapeutics and published an International Patent Application describing a system for identifying agitation episodes. While the term “agitated” is often colloquially understood to mean “irritated”, “anxious”, and/or “upset”, it is a pathological hallmark of various diseases. As such, for detecting and preventing the early onset of agitation in predisposed to highly agitated behavior, the teams at MindMed and BioXcel have developed a state-of-the-art digital therapeutics tool to facilitate both caregivers and patients identify agitation symptoms before they arise. The disclosure provides a method for measuring the signs of an impending agitation event and alerts the caregiver to treat the subject before agitation symptoms arise.

Agitation is not its illness but rather a symptom of a single illness or …

Full story available on Benzinga.com

More Psychedelic Front Runners MindMed , BioXcel Patent System To Identify Agitation